Sai Parenteral's Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹372 - ₹392
- Lot size
- 38 shares
- Issue amount
- ₹408.79 cr
- Total subscription
- 1.08×
- Opens
- 24 Mar 2026
- Closes
- 27 Mar 2026
- Allotment
- 30 Mar 2026
- Listing
- 2 Apr 2026
Offer at a glance
Issue overview
- Issue size
- 1,04,28,288 shares
- Face value
- ₹5 per share
- Minimum investment
- ₹14,136
- Fresh issue
- ₹285 cr
- Offer for sale
- ₹123.79 cr
- Registrar
- Bigshare Services Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,896
- Issue type
- Bookbuilding IPO
- Shares before issue
- 3,69,08,823
- Shares after issue
- 4,41,79,231
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 38 | ₹14,896 |
| sHNI | 14 | 532 | ₹2,08,544 |
| bHNI | 68 | 2,584 | ₹10,12,928 |
Share reservation
Subscription & GMP
Subscription by category
Reported 27 Mar 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 96,050 | 7,651 |
| HNIs(10L +) | 1,960 | 160 |
| HNIs (2-10L) | 980 | 127 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 81.76 | 141.52 |
| FIIs | 0 | 72.53 |
| FIs | 0 | 20 |
| Mutual Funds | 0 | 30 |
| Others | 0 | 19 |
| RETAIL | 143.08 | 17.22 |
| HNIs 2+ | 20.44 | 4.87 |
| HNIs 10+ | 40.88 | 145.33 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Sep-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| EPS | 2.82 | 6.16 | 10.54 | 5.43 |
| ROE | 0 | 0 | 0 | 0 |
| ROCE | 9.28 | 28.92 | 20.52 | 21.04 |
| RONW | 0 | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 72.19 | 0 | 0 |
| POST IPO(PE) | 0 | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Gland Pharma Limited | 44.71 | 1895.70 | 1.00 | 555.41 | 7.63 | 42.40 |
| Sai Parenteral's Limited | 72.19 | 392.00 | 5.00 | 35.98 | 15.09 | 5.43 |
| Sai Life Sciences Limited | 107.70 | 879.15 | 1.00 | 102.12 | 7.99 | 8.83 |
| Innova Captab Limited | 32.45 | 727.20 | 10.00 | 167.66 | 13.37 | 22.41 |
| Senores Pharmaceutic als Limited | 64.3 | 817.65 | 10.00 | 176.37 | 7.18 | 16.12 |
Company information
Company profile
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical company engaged in the research, development, and manufacturing of formulations, operating across two main segments: branded generic formulations and contract development and manufacturing (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology, with offerings available in various dosage forms including injectables, tablets, capsules, liquid orals, and ointments. The company serves a wide customer base including government agencies, pharmaceutical companies, hospitals, and distributors across India, and expanded into exports in FY 2023 after acquiring internationally accredited facilities in Hyderabad, enabling supply to markets like Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral's operates five manufacturing facilities in India, four in Hyderabad and one through its wholly owned subsidiary Revat Laboratories in Ongole, Andhra Pradesh, all equipped with GMP and global certifications, and as of August 31, 2025, the company had 277 full-time employees.
Strengths
- Diversified Formulations Portfolio: Presence across multiple therapeutic segments and dosage forms reduces dependence on a single product.
- Accredited Manufacturing Facilities: WHO-GMP and international certifications like TGA and PIC/S enhance credibility and enable access to regulated markets.
- Strong CDMO Focus: CDMO capabilities support long-term contracts, better margins, and global partnerships.
Risk factors
- Geographical Concentration Risk: Manufacturing facilities are mainly located in Telangana and Andhra Pradesh, exposing operations to regional disruptions and regulatory changes.
- Dependence on Injectable Segment: A significant share of revenue comes from injectable products, increasing vulnerability to demand fluctuations in this segment.
- Regulatory Compliance Risk: Ongoing inspections and audits create risk, as any adverse findings may impact operations, reputation, and financial performance.
Promoters
Anil Kumar Karusala
Vijitha Gorrepati
Karusala Aruna
Registrar & documents
Lead manager
Arihant Capital Markets Limited
Registrar & contacts
Bigshare Services Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Plot No 39 5th floor, Lavanya Arcade Jayabheri Enclave Gachibowli, K.V.Rangareddy, Seri Lingampally Hyderabad, Telangana, 500032
+91 79979 91301
[email protected]Company website ↗Understanding SAIPARENT IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.